可生物学解释的CT影像组学模型预测胰腺导管腺癌三级淋巴结构状态并分层化疗免疫治疗结局
本研究回顾性纳入435例病理确诊胰腺导管腺癌患者,基于术前CT影像组学特征构建XGBoost模型(RaTLS)预测三级淋巴结构状态,在四个队列中AUC为0.891、0.835、0.794、0.722,并显示RaTLS-high患者客观缓解率更高、无进展生存期更长,且RaTLS与免疫治疗队列无进展生存期独立相关(P=0.029)。
要点
- 术前CT影像组学模型可无创预测PDAC三级淋巴结构状态,外部验证AUC 0.794。
- RaTLS-high提示免疫化疗后客观缓解率更高、无进展生存期更长。
- 放射基因组分析提示模型与B细胞及趋化因子通路相关。
核心结论
- 基于CT的RaTLS模型有望无创预测PDAC三级淋巴结构状态,并可能为免疫治疗患者结局分层提供附加价值。
研究设计与样本
- 回顾性多队列研究,共纳入435例病理确诊PDAC患者,分为训练组170例、时间验证组71例、外部验证组63例、放射基因组验证组50例和免疫治疗队列81例。
- 基于术前CT影像组学特征,经序列特征选择后采用XGBoost构建RaTLS模型。
- 放射基因组分析取影像定义与病理定义TLS组间差异表达基因交集,并将所得特征投射至TCGA-PAAD验证。
- 临床结局采用客观缓解率和无进展生存期评估。
诊断标准与关键数值
- RaTLS模型在四个队列的AUC分别为0.891、0.835、0.794和0.722,校准满意且决策曲线净获益为正。
- 放射基因组整合识别522个一致基因,富集于B细胞和趋化因子程序,相应特征在TCGA-PAAD中与总生存期独立相关(P=0.002)。
- RaTLS-high患者客观缓解率更高、无进展生存期更长,多因素校正后RaTLS仍与无进展生存期独立相关(P=0.029)。
临床应用与阅片要点
- 阅片时可关注术前CT影像组学特征,辅助无创评估PDAC三级淋巴结构状态。
- RaTLS-high可能提示免疫检查点抑制剂联合化疗后更好的治疗反应和预后。
局限性
- 原文未明确报告研究局限性。
- 研究为回顾性设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop and validate a CT-based radiomic model for non-invasive prediction of tertiary lymphoid structure (TLS) status in pancreatic ductal adenocarcinoma (PDAC), and to evaluate its biological correlates and association with clinical outcomes among patients receiving immune checkpoint inhibitors (ICIs) plus chemotherapy.
MATERIALS AND METHODS: A total of 435 patients with pathologically confirmed PDAC were retrospectively included in training (n = 170), temporal validation (n = 71), external validation (n = 63), radiogenomic validation (n = 50), and an immunotherapy cohort (n = 81). Radiomic features from preoperative CT were used to construct the RaTLS model with XGBoost after sequential feature selection. Radiogenomic analysis intersected differentially expressed genes between imaging- and pathology-defined TLS groups, and the resulting signature was projected into TCGA-PAAD for validation. Clinical outcomes were evaluated using objective response rate and progression-free survival.
RESULTS: The RaTLS model achieved AUCs of 0.891, 0.835, 0.794, and 0.722 across the four cohorts, with satisfactory calibration and positive decision-curve net benefit. Radiogenomic integration identified 522 concordant genes enriched in B cell and chemokine programs, and the corresponding signature was independently associated with overall survival in TCGA-PAAD (P = 0.002). RaTLS-high patients showed a higher objective response rate and longer progression-free survival, with RaTLS remaining independently associated with progression-free survival after multivariable adjustment (P = 0.029).
CONCLUSIONS: The CT-based RaTLS model shows promise for non-invasive prediction of TLS status in PDAC and may offer additional value in outcome stratification among patients receiving immunotherapy-based treatment.
引用
- Zhao C, Zeng C, Huang J, et al. A biologically Interpretable CT radiomic model Predicts tertiary lymphoid structure status and Stratifies outcomes following chemoimmunotherapy in pancreatic ductal adenocarcinoma. Eur J Radiol. 2026. PMID: 42721921. doi:10.1016/j.ejrad.2026.113228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。